Zydus Lifesciences has entered into a licensing and supply agreement with Lupin to co-market its innovative Semaglutide Injection in India, aimed at expanding access to advanced therapies for diabetes and weight management.
According to the press release dated March 17, Lupin will receive semi-exclusive rights to market the product in India under the brands Semanext and Livarise, while Zydus will market the drug under Semaglyn, Mashema, and Alterme.
Under the agreement, Lupin will pay Zydus upfront licensing fees along with milestone-based payments, linked to predefined targets. The collaboration combines Zydus’ product development capabilities with Lupin’s extensive market reach in India to enhance patient access to GLP-1 based therapies.
The Semaglutide injection, delivered via a reusable pen device, is indicated for adults with type 2 diabetes mellitus who require improved glycaemic control, either as monotherapy or in combination with other treatments. It is also prescribed for chronic weight management in adults with obesity or overweight conditions along with related comorbidities.
Both companies highlighted that the partnership aims to strengthen their presence in the cardio-metabolic segment while addressing unmet patient needs in India’s growing diabetes and obesity market.
Zydus stated that the collaboration is focused on improving patient convenience and therapy outcomes, while Lupin emphasized that the agreement will enhance its diabetes portfolio and support healthcare professionals with advanced treatment options.